Meeting the Clinical Needs of Patients

Nubratori RX currently has 12 products on the market.
These products are sold under the FDA Structured Product Listing,
Market Category, C181659: Outsourcing Facility Compounded Human Drug Product
(Exempt From Approval Requirements). Click image to enlarge.

Dexonto™ is a topical formulation of dexamethasone to be used with iontophoresis.
Diclofono™ is a topical formulation for diclofenac to be used with ultrasound.
Frotek™ is a topical formulation of ketoprofen.
Lidocidex™ is a sterile formulation consisting of lidocaine and dexamethasone.
Lidomar™ is a sterile formulation consisting of lidocaine and bupivicane.
Neuraptine™ is a topical formulation of gabapentin.

Dexonto 0.4%, is a topical formulation of dexamethasone for iontophoresis.

Diclofono 1.6%, is a topical formulation of diclofenac to be used with or without ultrasound.

Frotek 10%, is a topical formulation of ketoprofen.

Lidocidex is an injectable sterile formulation consisting of lidocaine and dexamethasone.

Lidomar is an injectable sterile formulation consisting of lidocaine and bupivicane.

Neuraptine 10%, is a topical formulation of gabapentin. 

Nubratori RX currently has ten additional products in the pipeline designed for non-opiate pain control for orthopedics, neurologists, and others in the pain management health care sector.

 

For more information on any of these formulations, please contact us and also peruse the section on white papers and articles, found here.

 

Nubratori RX products are batch tested, validated, and put through the required stability and potency testing prior to being released to the market.

 

Let us know how we can help you.

NubratoriLogoFDATag-01.png

381 Van Ness Ave Suite 1507, Torrance, CA 90501

1094653.jpeg